- Home
- SYRE vs BBNX Comparison
SYRE vs BBNX Comparison
Compare SYRE & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- BBNX
- Stock Information
- Founded
- SYRE 2013
- BBNX 2015
- Country
- SYRE United States
- BBNX United States
- Employees
- SYRE N/A
- BBNX N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- BBNX Medical/Dental Instruments
- Sector
- SYRE Health Care
- BBNX Health Care
- Exchange
- SYRE Nasdaq
- BBNX Nasdaq
- Market Cap
- SYRE 1.1B
- BBNX 967.6M
- IPO Year
- SYRE 2016
- BBNX 2025
- Fundamental
- Price
- SYRE $16.23
- BBNX $22.23
- Analyst Decision
- SYRE Strong Buy
- BBNX Strong Buy
- Analyst Count
- SYRE 6
- BBNX 10
- Target Price
- SYRE $57.60
- BBNX $26.10
- AVG Volume (30 Days)
- SYRE 681.2K
- BBNX 1.1M
- Earning Date
- SYRE 11-06-2025
- BBNX 11-06-2025
- Dividend Yield
- SYRE N/A
- BBNX N/A
- EPS Growth
- SYRE N/A
- BBNX N/A
- EPS
- SYRE N/A
- BBNX N/A
- Revenue
- SYRE N/A
- BBNX $78,022,000.00
- Revenue This Year
- SYRE N/A
- BBNX $42.80
- Revenue Next Year
- SYRE N/A
- BBNX $34.58
- P/E Ratio
- SYRE N/A
- BBNX N/A
- Revenue Growth
- SYRE N/A
- BBNX 550.45
- 52 Week Low
- SYRE $10.91
- BBNX $8.89
- 52 Week High
- SYRE $40.26
- BBNX $26.66
- Technical
- Relative Strength Index (RSI)
- SYRE 52.04
- BBNX 56.62
- Support Level
- SYRE $15.87
- BBNX $19.07
- Resistance Level
- SYRE $17.18
- BBNX $23.08
- Average True Range (ATR)
- SYRE 0.88
- BBNX 1.32
- MACD
- SYRE 0.08
- BBNX -0.24
- Stochastic Oscillator
- SYRE 70.65
- BBNX 70.86
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.